My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpha Cognition Inc. - Common Stock (NQ:ACOG)

7.200 -0.170 (-2.31%)
Streaming Delayed Price Updated: 11:12 AM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alpha Cognition Inc. - Common Stock

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences
From Alpha Cognition Inc.
Via Business Wire
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025
Dallas, Texas--(Newsfile Corp. - August 15, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate... 
Via Newsfile
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate... 
Via Newsfile
Topics Intellectual Property
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference
From Alpha Cognition
Via Business Wire
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
From Alpha Cognition Inc.
Via Business Wire
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on... 
Via Newsfile
Topics Intellectual Property
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
From Alpha Cognition Inc.
Via Business Wire
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)
Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on... 
Via Newsfile
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
From OTC Markets
Via GlobeNewswire
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China
From Alpha Cognition, Inc.
Via Business Wire
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Partial Exercise of Over-allotment Option
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Voluntary Delisting from CSE
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.